The authors analyze if there is an inverted U-shaped relation between competition and R&D. Results show that the inverted U-shaped relation is supported by the Herfindahl index but not by the price cost margin.
This paper looks at the increasing trend around the world to evaluate the quantity and quality of universities’ research output. Methods of evaluating university research output deployed across countries are discussed.
This paper looks at the reasons for Canada’s low business research and development (R&D) intensity. R&D performance across OECD countries is examined, and a detailed decomposition is undertaken of differences between Canadian and U.S.
This study uses the Clinton Administrations Health Security Act of 1993 as a natural experiment to show how threats of price constraints affect firm-level R&D spending.
In analyzing cooperation in R&D in the form of research joint ventures, the authors show that the optimal size of an RJV does not only depend on the degree of spillovers, as literature suggests, but also on the cost function of R&D activities.
This report is the second of two publications containing results from the 2001 Survey of Industrial Research and Development. It contains the full set of statistics produced from the survey including statistics on R&D funding during the calender year 2001 and on R&D personnel in January 2002.
The aim of the study is to optimize the transformation of knowledge dissemination in Canada. To achieve national public policy objectives, Canada needs an efficient, effective and sustainable system for the dissemination of scholarly research, according to the report.
The paper studies R&D investment decisions of a firm facing the threat of new technology entry and subject to technical uncertainty. The authors distinguish four scenarios: inevitable entry, entry deterrence, entry blockade, and non-credible entry threat.
The paper discusses the properties of scientific and technological knowledge and the institutions supporting its generation and its economic applications.
Using Monte Carlo techniques, the authors model how future price controls in the U.S. will impact early-stage product development decisions in the pharmaceutical industry.